FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development

A major push to sharpen the future of cancer treatment is underway

WHO unites 800+ institutions in historic global health push to prepare for next pandemic threat

Scientists at the forum warned of an increasingly volatile health landscape

Kauvery Hospital conducts 4th edition of ECG Masterclass 2026; 400+ medical professionals attend

Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”

Cadila Pharma launches triple-combination therapy for stronger BP control

The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

Stereotaxis bags FDA clearance for next-gen cath lab tech

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Alembic Pharma wins USFDA nod for generic Dapagliflozin, secures 180-day exclusivity

Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.

Practo reports surge in lifestyle disease awareness within Tier 2 cities, led by metabolic health searches

Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations